Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 7:01 AM

Published 07/02/2009 by ShareCast


TechMARK movers: Elan up on Johnson & Johnson deal

LONDON (SHARECAST) - Shares in Elan rallied on news that Johnson & Johnson will acquire substantially all of the assets and rights of the Irish drug firm related to its Alzheimer's Immunotherapy Program. Johnson & Johnson, through its affiliate, will invest $1bn in Elan in exchange for...

Share this 

What others report on the same story

J&J to take $1bn stake in Ireland's Elan
Johnson & Johnson, the US healthcare products group, is to take a $1bn (£600m) minority stake in Elan and commit at least $500m more to help fund development of ... - [07/03/2009 - FT.com - Health]
J&J takes $1bn Elan stake
Johnson & Johnson to buy 18 per cent of Irish-American biotech company. Deal ends months of uncertainty over group's financial stabiltity ... - [07/02/2009 - FT.com - Health]
Elan Shares Rise on J&J Investment
Elan(ELN Quote) shares rose Thursday after health care giant Johnson & Johnson(JNJ Quote) said it was spending $1 billion to acquire a minority stake in the Irish ... - [07/02/2009 - TheStreet.com]
J&J buys $1 billion stake in Elan, shares soar - [07/02/2009 - Reuters: Business News]
J&J buys $1 billion stake in Elan, shares soar - [07/02/2009 - Reuters: Deals]
J&J takes $1bn Elan stake - [07/02/2009 - FT.com - Companies]
J&J takes $1bn Elan stake - [07/02/2009 - FT.com - Companies US & Canada]
J&J takes $1bn Elan stake - [07/02/2009 - FT.com - Companies, Europe]
1

Related Stories

First Reported 07/03/2009 - Updated 07/03/2009 - 1 Documents (in Internet & IT)
Food and Drug Administration - Click to view 360-page
Food and Drug Administration
Sanofi-aventis' Multaq receives US FDA nod to treat patients with atrial fibrillation or atrial flutter
Sanofi-aventis announced that the US Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management ... [PharmaBiz - 07/03/2009]
First Reported 07/01/2009 - Updated 07/01/2009 - 1 Documents (in Health)
Sanofi-Aventis SA - Click to view image in its original context
Sanofi-Aventis SA
FDA to Review Sanofi Drug's Safety
The FDA advised patients to continue taking Sanofi-Aventis's Lantus, despite recent studies showing the diabetes drug may be linked to cancer risks. ... [WSJ.com: What's News US - 07/01/2009]
First Reported 07/02/2009 - Updated 07/02/2009 - 1 Documents
Elan Corporation, plc - Click to view image in its original context
Elan Corporation, plc
Options Edge: Continental Airlines, NRG Energy, Elan Corporation, and Netflix
Today's column includes a bullish note for Continental Airlines, Inc. (CAL), an aggressive takeover offer for NRG Energy, Inc. (NRG), a lucrative investment for Elan Corporation, plc (ELN), and positive comments on Netflix, Inc. (NFLX). Each day, Options ... [Schaeffers Research - 07/02/2009]
In Focus
Network

Blogs

sort by: Date | Relevance
Sanofi-Aventis's 'Voluntary' Staff Departures [Healthcare Sector and Stocks Analysis from Seek ... - 07/01/2009]
Derek Lowe submits: Sanofi Aventis (SNY) said "no layoffs" in the company's announcement yesterday, but is instead counting on "voluntary staff departures". Here's ...
How Bad Is Sanofi's Safety Scare? [Healthcare Sector and Stocks Analysis from Seek ... - 06/28/2009]
Mike Huckman submits: Shares of the French drugmaker are getting pummeled over at least three analyst reports identifying a leak about a study or studies that could ...
Sanofi-Aventis: Strong Pipeline, Possible Mid-S... [Healthcare Sector and Stocks Analysis from Seek ... - 06/26/2009]
Zacks.com submits: By Jason Napodano, CFA & Brian Marckx, CFASanofi-Aventis (SNY) posted EPS of €5.36 in 2008, an increase of just 2% from 2007. Revenue fell 1% ...
Sanofi to Dive Further into Generic Drug-Making... [WSJ.com: Health Blog - 06/25/2009]
Another large drug maker is poised to expand its generic medicine business. This time it’s French-based heavyweight Sanofi-Aventis that wants to sell more in generics, ...
Sanofi-Aventis Stock Recovering After Lantus Leak [Healthcare Sector and Stocks Analysis from Seek ... - 06/30/2009]
Mike Huckman submits: Shares of Sanofi-Aventis (SNY) are getting a little investor injection on the back of the emergency release of the Lantus diabetic insulin ...
1 2 3 4

  •  
  •  
  •